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Background: This study aimed to determine the sensitivity and 
specificity of reverse transcription PCR (RT-PCR) testing of upper 
respiratory tract (URT) samples from hospitalised patients with 
coronavirus disease 2019 (COVID-19), compared to the gold standard 
of a clinical diagnosis. 
Methods: All URT RT-PCR testing for severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2) in NHS Lothian, Scotland, 
United Kingdom between the 7th of February and 19th April 2020 
(inclusive) was reviewed, and hospitalised patients were identified. All 
URT RT-PCR tests were analysed for each patient to determine the 
sequence of negative and positive results. For those who were tested 
twice or more but never received a positive result, case records were 
reviewed, and a clinical diagnosis of COVID-19 allocated based on 
clinical features, discharge diagnosis, and radiology and haematology 
results. For those who had a negative RT-PCR test but a clinical 
diagnosis of COVID-19, respiratory samples were retested using a 
multiplex respiratory panel, a second SARS-CoV-2 RT-PCR assay, and a 
human RNase P control. 
Results: Compared to the gold standard of a clinical diagnosis of 
Open Peer Review




26 Oct 2020 report report
James Otieno , Icahn School of Medicine 
at Mount Sinai, New York City, USA 
Fogarty International Center, NIH, Bethesda, 
USA
1. 
Mariska Leeflang, Amsterdam University 
Medical Centers, University of Amsterdam, 
Amsterdam, The Netherlands
2. 
Any reports and responses or comments on the 
 
Page 1 of 12
Wellcome Open Research 2020, 5:254 Last updated: 08 FEB 2021
Corresponding author: Kate E. Templeton (Kate.Templeton@nhslothian.scot.nhs.uk)
Author roles: Williams TC: Conceptualization, Formal Analysis, Investigation, Methodology, Project Administration, Visualization, 
Writing – Original Draft Preparation, Writing – Review & Editing; Wastnedge E: Formal Analysis, Investigation, Writing – Original Draft 
Preparation, Writing – Review & Editing; McAllister G: Formal Analysis, Investigation, Writing – Original Draft Preparation, Writing – 
Review & Editing; Bhatia R: Formal Analysis, Investigation; Cuschieri K: Data Curation, Resources, Writing – Review & Editing; Kefala K: 
Conceptualization, Resources, Supervision, Writing – Review & Editing; Hamilton F: Data Curation, Investigation, Resources, Supervision, 
Writing – Review & Editing; Johannessen I: Conceptualization, Investigation, Resources, Supervision, Writing – Original Draft 
Preparation, Writing – Review & Editing; Laurenson IF: Conceptualization, Investigation, Methodology, Supervision, Writing – Original 
Draft Preparation, Writing – Review & Editing; Shepherd J: Investigation, Writing – Review & Editing; Stewart A: Resources, Writing – 
Review & Editing; Waters D: Investigation, Writing – Review & Editing; Wise H: Data Curation, Investigation, Writing – Original Draft 
Preparation, Writing – Review & Editing; Templeton KE: Conceptualization, Funding Acquisition, Methodology, Project Administration, 
Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing
Competing interests: No competing interests were disclosed.
Grant information: TCW receives funding from the Wellcome Trust [204802]. 
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Copyright: © 2020 Williams TC et al. This is an open access article distributed under the terms of the Creative Commons Attribution 
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite this article: Williams TC, Wastnedge E, McAllister G et al. Sensitivity of RT-PCR testing of upper respiratory tract samples 
for SARS-CoV-2 in hospitalised patients: a retrospective cohort study [version 1; peer review: 1 approved, 1 approved with 
reservations] Wellcome Open Research 2020, 5:254 https://doi.org/10.12688/wellcomeopenres.16342.1
First published: 26 Oct 2020, 5:254 https://doi.org/10.12688/wellcomeopenres.16342.1 
COVID-19, the sensitivity of a single upper respiratory tract RT-PCR for 
COVID-19 was 82.2% (95% confidence interval 79.0-85.1%).   The 
sensitivity of two upper respiratory tract RT-PCR tests increased 
sensitivity to 90.6% (CI 88.0-92.7%). A further 2.2% and 0.9% of 
patients who received a clinical diagnosis of COVID-19 were positive 
on a third and fourth test; this may be an underestimate of the value 
of further testing as the majority of patients 93.0% (2999/3226) only 
had one or two URT RT-PCR tests. 
Conclusions: The sensitivity of a single RT-PCR test of URT samples in 
hospitalised patients is 82.2%. Sensitivity increases to 90.6% when 
patients are tested twice.  A proportion of cases with clinically defined 
COVID-19 never test positive on URT RT-PCR despite repeat testing.
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Introduction
The coronavirus disease 2019 (COVID-19) pandemic in Europe 
has already caused significant morbidity and mortality, not 
least within the United Kingdom. As well as causing large num-
bers of community-acquired cases, severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2) has also been shown 
to circulate effectively within hospitals1, necessitating the crea-
tion of COVID-19 specific areas. An estimate of the sensitivity 
of reverse transcription PCR (RT-PCR) testing for SARS-
CoV-2 is therefore critical. Overestimation of sensitivity may 
lead to patients with disease being incorrectly diagnosed, 
and placed in non-COVID-19 areas with the subsequent risk 
of infection to others; underestimation of sensitivity may lead 
to patients who are SARS-CoV-2 negative being erroneously 
placed in COVID-19 areas.
A recent meta-analysis2 estimates the sensitivity of reverse 
transcription polymerase chain reaction (RT-PCR) testing 
of upper respiratory tract (URT) samples as 89%, but this 
meta-analysis, and a subsequent one3 highlight a number of 
limitations in the literature. These include small sample size 
(<100 patients with COVID-19)4–11, reliance on RT-PCR 
itself as the gold standard for diagnosis12,13, use of computed 
tomography (CT) scans rather than clinical criteria as a gold 
standard for the diagnosis of COVID-1914,15, and absence of 
comprehensive RT-PCR testing for all included patients16. 
Finally, only a single study to our knowledge has examined the 
cumulative sensitivity of repeat testing for SARS-CoV-214. 
Here we examine in a large, comprehensive dataset the sensi-
tivity of RT-PCR testing of upper respiratory tract specimens 




All RT-PCR testing conducted for SARS-CoV-2 in NHS 
Lothian between the 7th of February and 19th April 2020 (inclu-
sive) was reviewed. NHS Lothian covers a population of 907,580 
people17 and during the period of the study the Royal Infir-
mary of Edinburgh was the only regional centre conducting 
SARS-CoV-2 testing. Hospitalised patients were identified by 
cross-matching patient identification numbers against the NHS 
Lothian TrakCare Patient Clinical Management System data-
base. In this study we comply with the STROBE reporting 
guidelines for observational studies18.
Data collection
For hospitalised patients, URT samples were identified, and 
only unambiguous positive or negative results, as authorised 
by laboratory staff, selected. Testing patterns were allocated for 
each patient, determining the sequence of URT RT-PCR tests 
and whether each test had yielded a negative or positive result 
(Table 1).
Case definitions
Patients with a single negative test result were classified as a 
true negative, as clinical guidelines in place at the time specified 
that if there was clinical suspicion of COVID-19, an URT 
RT-PCR test should be repeated if the first test was negative. 
For those who initially tested negative on one or more occa-
sions and then positive, case records were reviewed to determine 
whether this represented two discrete presentations or the same 
presentation. If they were classified as two distinct presenta-
tions, the negative followed by positive test was treated as a 
single positive test.
For those tested twice or more but who never received a posi-
tive result from URT RT-PCR testing, case records were 
reviewed, and a clinical diagnosis of COVID-19 was allocated 
based on a discharge diagnosis from the clinical team (or death 
certificate documentation) and clinical review. Clinical fea-
tures, radiology reports and haematology results were reviewed. 
A positive clinical diagnosis was based on European Centres 
for Disease Control (ECDC) and World Health Organisation 
(WHO) criteria19. Based on previously published studies20,21, 
cases were judged to be more likely to represent COVID if 
a chest X-ray showed patchy bilateral infiltrative changes, 
or a CT scan showed ground glass changes and if there was 
lymphopaenia in the presence of a normal neutrophil count22. 
Case records were reviewed by two clinicians (EW and TCW); 
if a consensus decision could not be reached, the case records 
were reviewed by a third clinician (DW) to arrive at a final 
clinical diagnosis. For patients classified as a possible false 
negative, their initial respiratory sample was retested using a 
Table 1. Classification of test results.
Description Classification
Single negative test Classified as a true negative.
Initial positive test, with or without 
subsequent testing.
Classified as a true positive. Clinical records reviewed to confirm that met case definition.
More than one negative test, no 
positive test result at any point
Clinical records reviewed to identify whether should be classified as true negative, or 
potential false negative based on clinical diagnosis.
A series of one or more negative tests 
followed by a positive test, with or 
without subsequent testing.
Clinical records reviewed to identify whether a single or multiple clinical presentations. If two 
distinct clinical presentations with independent testing, treated as discrete episodes, and test 
classified as a true positive. If a single episode, test classified as a false negative.
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multiplex respiratory panel, a second SARS-CoV-2 RT-PCR 
assay on the SeeGene platform as detailed below, and a human 
RNase P RT-PCR.
For patients who tested positive on their initial test, case records 
were reviewed to ensure they met the clinical criteria for 
COVID-19, as described above. If they did not meet these clini-
cal criteria, the samples IDs were matched against samples 
which had undergone whole genome sequencing (WGS) as 
part of the COVID-19 Genomics UK sequencing consortium23. 
If WGS had been completed successfully for a sample, this was 
assumed to represent a true positive. For those that had not, 
RT-PCR re-testing was conducted using the SeeGene platform 
as detailed below. 
Laboratory methods
URT samples were collected and added to viral transport 
media (Remel MicroTest M4RT). A volume of 110 µL of eluate 
containing purified RNA was obtained following automated 
extraction carried out on the NucliSENS® easyMag® 
(bioMérieux) using an ‘off-board’ extraction where 200 µL of 
the sample was added to 2 ml of easyMAG lysis buffer. Overall, 
94.0% (5418/5763) of tests on hospitalised patients were con-
ducted using a modified in-house RT-PCR (Drosten, Euro-
surveillance24) 5.8% (337/5763) were conducted using the 
Allplex™2019-nCoV Assay from SeeGene (Seoul, South Korea), 
and 0.15% (8/5763) using the Abbott RealTime SARS-CoV-2 
assay (Des Plaines, IL), with cut-off for diagnosis a threshold 
cycle (Ct) of 40 or less.
Further characterisation of possible false negatives
The Luminex Panel NxTAG® Respiratory Pathogen Panel 
(Texas, United States) was used to re-test the original extracted 
RNA for suspected false negatives (cases which met the clini-
cal case criteria but had negative RT-PCR testing). Multiplex 
real-time PCRs were carried out on positive extracts using the 
ABI real-time system, model 7500 (Applied Biosystems, War-
rington, United Kingdom), as part of routine testing using 
assays developed in-house and/or adapted from published 
methods25,26. The same samples were also re-tested using the 
Allplex™2019-nCoV SeeGene Assay, and using a human 
RNase P control27. For samples that tested positive using the 
SeeGene assay,  Ct values for human RNase P were compared 
to negative results using a Welch two-sample t-test in R version 
3.4.128 and plotted using GraphPad Prism version 6.04 for 
Windows (GraphPad Software, La Jolla California USA).
For patients who tested positive for a new respiratory patho-
gen, the case records were reviewed to ascertain whether the 
diagnosis was best explained by SARS-CoV-2 infection or the 
subsequently identified respiratory pathogen. Convales-
cent serology samples (>14 days after onset of symptoms), if 
available, were analysed using the Abbott SARS-CoV-2 IgG 
assay on the Abbott Architect platform29.
Statistical analyses
The sensitivity was calculated as the proportion of true posi-
tives detected on initial testing and re-testing of suspected 
false negatives, divided by the number of true positives added 
to convincing false negatives, as estimated on the basis of fur-
ther respiratory testing and serology testing. The specificity 
was calculated by dividing true negatives by the number of 
true negatives added to those judged to be false positives, on 
the basis of repeat RT-PCR retesting. The positive predictive 
value was determined by dividing the number of true positive 
by the sum of the true positives and false positives. The 
negative predictive value was calculated by dividing the number 
of true negatives by the sum of the true negatives and false 
negatives. Confidence intervals for these estimates were calcu-
lated using a two-sided exact binomial test with a confidence 
level of 0.95, implemented in R28.
Ethics statement
As part of the study protocol, specimens and associated clini-
cal data were collected and anonymized before additional 
molecular/serological testing in accordance with local ethical 
approval (South East Scotland Scottish Academic Health 
Sciences Collaboration Human Annotated BioResource reference 
no. 10/S1402/33). As the study formed part of a service evalua-
tion, with no publication of patient identifiable information, the 
need for informed consent was waived by the local Caldicott 
Guardian.
An earlier version of this article can be found on medRxiv 
(DOI: https://doi.org/10.1101/2020.06.19.20135756).
Results
A total of 10,601 RT-PCR tests for SARS-CoV-2 for 8311 patients 
were conducted on URT specimens by the Royal Infirmary 
of Edinburgh laboratories between the 7th of February and the 
19th of April 2020 on patients for whom data was available. 
These tests included community testing for patients who were 
never admitted to hospital, and testing for patients outside NHS 
Lothian for Boards that did not perform their own SARS-CoV-2 
testing. From this testing, 1667 patients received a positive 
result for SARS-CoV-2 testing (Table 2). The overall sensitiv-
ity of an initial URT RT-PCR test for the whole cohort (using a 
gold standard of an eventual molecular diagnosis of SARS-
CoV-2 on URT RT-PCR) is 91.8%, rising to 98.4% after 
2 tests.
Testing for other respiratory pathogens
Of the total cohort, 3226 patients were hospitalised in NHS 
Lothian. The data analysis for these patients is summarised in 
the flowchart in Figure 1. In total, 73 patients received a clini-
cal diagnosis of COVID-19 but did not receive a positive 
RT-PCR result at the time. The RNA extract used for the initial 
SARS-CoV-2 RT-PCR was retested for common respiratory 
pathogens using the Luminex assay. Out of the 73, nine 
(12.3%) tested positive for a respiratory pathogen. On clinical 
review, all nine cases were judged to be better explained by 
this new diagnosis rather than COVID-19 (Table 3).
Retesting with the Seegene assay
Retesting of the remaining 64 samples from suspected false 
negative cases with the Seegene assay for SARS-CoV-2 
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Table 2. Summary of testing for all patients.
Testing pattern Number % all patients % of positive patients
Single negative test 5665 68.1 NA
More than 1 negative test 979 11.8 NA
Single positive test 1531 18.4 91.8
Initial negative test followed by positive test 110 1.3 6.6
Positive test after two or more negative tests 26 0.3 1.6
Table 3. Positive results for other respiratory 
viruses on re-testing of initial sample.
Respiratory pathogen Number of cases
Influenza B 3
Human rhinovirus/enterovirus 2
Parainfluenza virus 1 1
Parainfluenza virus 3 1
Parainfluenza virus 4A 1
Human coronavirus NL63 1
Total 9
Figure 1. Flowchart for patients undergoing upper respiratory tract RT-PCR testing in NHS Lothian. URT: upper respiratory tract; 
RT-PCR: reverse transcription polymerase chain reaction; WGS: whole genome sequencing; COG-UK: COVID-19 Genomics Consortium.
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showed 27 (42.2%) of these were positive. Of the 37 remaining 
samples that neither tested positive for a respiratory patho-
gen nor for SARS-CoV-2 on repeat testing, all showed a posi-
tive result for human RNase P. Comparing Ct values for human 
RNase P for the samples that tested positive compared to those 
that tested negative (for SARS-CoV-2 on the Seegene assay) 
showed no difference using a Welch two sample t-test (p=0.49, 
Figure 3. The flowchart in Figure 2 summarises the results for 
the patients with a clinical assessment of COVID-19 but nega-
tive initial URT RT-PCR testing. For an initial test, the sensitivity 
of RT-PCR URT for SARS-CoV-2 infection was 82.2% (95% 
confidence interval 79.0–85.1%) with a specificity of 100% 
(CI 99.9–100%). The positive predictive value of an initial 
test was 100%; the negative predictive value of an initial test 
was 95.7% (Table 4).
Repeat testing
Sensitivity increased to 90.6% (CI 88.0-92.7%) after two 
consecutive tests (Table 5), with a specificity of 100% (CI 
99.9–100%). Increasing to three tests captured an additional 
14/646 (2.2%) patients, and up to four tests an additional 6/646 
(0.9%). This is a potential underestimate, as in this cohort there 
were 20 patients with a clinical diagnosis of COVID-19 who 
were tested twice with consecutive negative results, who 
might have yielded a positive result on a third test. The posi-
tive predictive value of two tests was 100%, and the negative 
predictive value 97.7%.
Lower respiratory tract samples
We examined data for a subset of 67 patients >16 years of 
age admitted to an Intensive Care Unit in NHS Lothian from 
the 6th March until the 5th of April 2020 with a discharge diag-
nosis of COVID-19. All tested positive on upper or lower respi-
ratory tract RT-PCR testing. The sensitivity of an initial URT 
RT-PCR test in this cohort was 76.1% (51/67 positive, CI 
64.1–85.7%). After two URT RT-PCR tests, sensitivity increased 
to 89.5% (60/67 positive, CI 79.7–95.7%). Four patients never 
tested positive on URT RT-PCR (6.0%). A total of 34 patients 
had a lower respiratory tract (LRT) sample sent for RT-PCR: 
the sensitivity of this initial test was higher than that of URT 
testing at 94.1% (32/34 positive). This dataset, with the extra 
information offered by the increased availability of LRT 
specimens, supports the overall findings from the study.
Convalescent serology
Out of the cohort of 64 patients who received a clinical diag-
nosis of COVID-19 with initial negative testing, and negative 








Table 4. A 2 x 2 contingency table to calculate 
sensitivity and specificity of URT RT-PCR for SARS-CoV-2 







Figure 2. Flowchart for patients meeting clinical diagnosis of 
COVID-19 but with negative upper respiratory tract RT-PCR 
testing.
Figure 3. Comparison of Ct values for human RNase P in URT 
sample RT-PCR tests which were positive or negative for 
SARS-CoV-2. Mean and standard deviation shown, p= 0.49 using 
Welch two sample t-test.
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testing for other viruses, convalescent serology (>14 days 
after onset of symptoms) was available for seven patients. Of 
these, four were positive (57.1%).
Discussion
Summary of principal findings
Here we show, using a comprehensively examined dataset, 
that the sensitivity of RT-PCR testing of URT specimens for 
the diagnosis of COVID-19 is 82.2% on initial testing, and 
90.6% after two consecutive tests. Subsequent tests showed 
a small increase in diagnostic yield (2.2% for three tests and 
a further 0.9% for four tests), although this may represent an 
underestimate, as a number of patients given a diagnosis of 
COVID-19 based on clinical criteria were only tested twice.
Findings of the present study in light of what has been 
published before
A previous meta-analysis gives a pooled sensitivity for 
RT-PCR of 89% (CI 81–94%) for the diagnosis of COVID-192; 
our results sit at the lower range of this estimate, but with 
overlapping confidence intervals. As highlighted in the introduc-
tion, the included studies suffer from a number of limitations 
including reliance on RT-PCR itself as the diagnostic gold 
standard, which would lead to an increase in the estimated sen-
sitivity. We are not aware of any studies which have used a 
clinical diagnosis of COVID-19 against which to assess the 
sensitivity of RT-PCR. Here we show that the sensitivity of an 
initial test is lower than reported in this meta-analysis, but 
that the chance of a false negative result (17.8%) is lower than 
the 29% estimated in a subsequent meta-analysis3 using a 
subset of studies included in 2. These widely varying esti-
mates highlight the importance of more data to inform our 
understanding of the strengths and weaknesses of RT-PCR 
testing.
Strengths and limitations
The strengths of the study include the large dataset of both 
COVID-19 positive and negative patients, and extensive further 
testing to rule out false negative RT-PCR results and alternative 
diagnoses in those patients given a clinical diagnosis of 
COVID-19. We also studied whether inadequate sampling 
might be a possible explanation for false negatives. However 
in a cohort of 37 possible false negatives all samples had detect-
able RT-PCR for human RNase P, with no difference between 
this group and those that tested positive for SARS-CoV-2, 
showing that this was not a factor in determining the sensitivity 
of RT-PCR in this population.
A limitation of the study is that the WHO/ECDC case defi-
nition of COVID-19 is likely to be highly sensitive but have 
low specificity. This means that a number of the cases we 
identified as potential false negatives could in fact represent 
other case presentations (a false positive in terms of the clini-
cal diagnosis), and thus underestimate the sensitivity of the 
assay. This interpretation is supported by the findings from 
serology, where four out of seven patients who met the clini-
cal case criteria and had a convalescent serology sample had 
a positive serological test. Conversely, we did not examine 
the case records of the 1837 patients who tested negative on a 
single occasion, some of whom are likely to have received 
a clinical diagnosis of COVID-19. An increased number 
of false negatives would lead to a decreased sensitivity for 
the assay.
Meaning of the study and understanding possible 
mechanisms
The result from our study suggest that there may be a small 
proportion of patients with SARS-CoV-2 infection who meet 
the clinical case definition but never test positive on RT-PCR 
testing. It is possible that, in patients with severe disease, 
infection is entirely in the LRT, or that by time of presenta-
tion in the disease course the virus may only be present at very 
low levels in the URT30; this is supported by our findings in 
the ICU cohort, where 6.0% of patients never tested positive 
on URT RT-PCR.
Implications for practice or policy, and suggestions for 
future research
Reliance on RT-PCR testing may result in patients with 
COVID-19 being inappropriately labelled with alternative diag-
noses. These possibly infectious patients will subsequently 
pose a risk to healthcare workers and other patients. A more 
detailed picture of the sensitivity of URT RT-PCR testing will 
be aided by comprehensive serological testing of hospitalised 
patients with suspected infection.
Data availability
Underlying data
As part of a service evaluation project, this study received 
local Caldicott Guardian approval but no permission was 
granted for publication of any patient identifiable information. 
Therefore, the raw data underlying the analyses has not been 
made publicly available. Anonymised data will be provided 
to researchers at accredited institutions who wish to conduct 
their own analysis or run meta-analyses after consultation with 
the local Institutional Review Board. Requests for access to 
the data should be made to Kate Templeton (kate.templeton@
nhslothian.scot.nhs.uk).
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The sensitivity of RTT-PCR for COVID-19 or SARS-CoV-2 infection is an estimate of much debate, so 
any study providing more information on what the actual sensitivity (and specificity) should be is 
very much desired. Although I wonder whether this is the study that will really provide us with the 
right answers, the conclusion (“Reliance on RT-PCR testing may result in patients with COVID-19 being 
inappropriately labelled with alternative diagnoses.”) will probably still be true.
Abstract, Results: “The sensitivity of two upper respiratory tract RT-PCR tests increased sensitivity 
to 90.6%”. Please rephrase. Suggestion: “Using two upper respiratory tract RT-PCR tests 
increased sensitivity to 90.6%”. 
 
1. 
Introduction: “Overestimation of sensitivity may lead to patients with disease being incorrectly 
diagnosed”. I think it is not necessarily the overestimation leading to misdiagnosis, but 
rather the sensitivity (and actually the fact that a test results in any false negative) in itself. 
 
2. 
The authors state that they comply with the STROBE guidelines for reporting, but as this is a 
diagnostic accuracy study, they should comply to STARD. 
 
3. 
From the methods section it is not direct clear who are the tested population: only 
hospitalized patients, or also people in the community, or both? Please be clear. 
 
4. 
The authors state that they ‘identified’ URT samples. What does this mean? Does this also 
mean that this is a retrospective study? 
 
5. 
Only unambiguous results were used, but this leads to a high risk of bias and I think that at 
least the total number of ambiguous test results should have been reported. Also, what 
happened to samples from patients with one or more ambiguous test results. Were these 
patients excluded, or only the ambiguous samples? And how many of the patients with only 
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Probably due to the retrospective nature, the assessment of the reference standard/gold 
standard was not blinded for the index test result (as the way the results were verified 
depended on whether there were one or more negative test results). This may have led to 




Please make it explicit whether the RT-PCR was part of the clinical diagnosis criteria. 
 
8. 
Please make it explicit whether the outcomes and diagnoses were known when the RT-PCR 
results were assessed. 
 
9. 
I was surprised that single negative test results were considered true negative and multiple 
negative test results were checked extra. To me, two or three negative test results would 
provide more certainty than only one negative test result. 
 
10. 
Please check the estimates of sensitivity and specificity reported in the abstract and in the 
full text. It seems that they are different. Maybe they are not, but then it may be helpful to 
explain the numbers a bit more in the full text. 
 
11. 
Also, I had difficulty in getting the numbers of tested patients right…Is it correct that over 
5000 patients were not included in the study? That is the majority of the eligible patients. 
Why was this? And could that have led to biased results? 
 
12. 
Title versus abstract: the title only mentions sensitivity, while the aim of the study (at least in 
the abstract) involves both sensitivity and specificity. Please be consistent in this. Also, if the 
aim of the study was to investigate specificity, why were potential false positives not further 
followed up? So maybe elucidating the specificity was not the aim of this study after all. 
 
13. 




General remark: also minor detail. I think that using the abbreviation URT is not necessary 
and does not improve the readability of the manuscript.
15. 
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Is the study design appropriate and is the work technically sound?
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Are sufficient details of methods and analysis provided to allow replication by others?
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If applicable, is the statistical analysis and its interpretation appropriate?
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Are all the source data underlying the results available to ensure full reproducibility?
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Are the conclusions drawn adequately supported by the results?
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I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
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The coronavirus disease 2019 (COVID-19) pandemic is a serious global problem and proper 
diagnosis of individuals is a key step in the control strategy. As stated by the authors, a wrongful 
diagnosis could either send positive individuals into non-COVID-19 areas where they could be a 
risk of infection to others or send negative individuals into COVID-19 areas with a risk of infection 
unto themselves. 
 
Using a large dataset, the authors highlight the importance of (i) not relying on a single method 
for diagnosis as a gold standard, either clinical or RT-PCR alone, and (ii) RT-PCR repeat testing that 
markedly improves test sensitivity. 
 
Minor comment: 
The single negative test classified as a true negative, were these cases that never met a clinical 
diagnosis of COVID-19 (hence not suspected as a false negative)? Or is it that no other samples 
were available/collected? Would the edit below bring more clarity? 
 
“Patients with a single negative test result were classified as a true negative if they never met a clinical 
diagnosis of COVID-19. The clinical guidelines in place at the time specified that if there was clinical 
suspicion of COVID-19, an URT RT-PCR test should be repeated if the first test was negative.”
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